Literature DB >> 31648714

Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week.

Shankar Kumar1, Emma Lim2, Adrian Covic3, Peter Verhamme4, Chris P Gale5, A John Camm6, David Goldsmith7.   

Abstract

Atrial fibrillation (AF) and chronic kidney disease (CKD) often coexist as they share multiple risk factors, including hypertension, diabetes mellitus, and coronary artery disease. Although there is irrefutable evidence supporting anticoagulation in AF in the general population, these data may not be transferable to the setting of advanced CKD, where the decision to commence anticoagulation poses a conundrum. In this cohort, there is a progressively increased risk of both ischemic stroke and hemorrhage as renal function declines, complicating the decision to initiate anticoagulation. No definitive clinical guidelines derived from randomized controlled trials exist to aid clinical decision-making, and the findings from observational studies are conflicting. In this review, the authors outline the pathophysiological mechanisms at play and summarize the limited existing data related to anticoagulation in those with concomitant CKD and AF. Finally, the authors suggest how to approach the decision of whether and how to use oral anticoagulation in these patients.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  atrial fibrillation; chronic kidney disease; direct oral anticoagulant; hemorrhage; stroke; vitamin K antagonist; warfarin

Mesh:

Substances:

Year:  2019        PMID: 31648714     DOI: 10.1016/j.jacc.2019.08.1031

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  28 in total

Review 1.  COVID-19 associated thromboinflammation of renal capillary: potential mechanisms and treatment.

Authors:  Xiaojing Chen; Chengyuan Yu; Haijiao Jing; Chunxu Wang; Xinyi Zhao; Jinming Zhang; Shuoqi Zhang; Huan Liu; Rujuan Xie; Jialan Shi
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

2.  Management of Adults with Newly Diagnosed Atrial Fibrillation with and without CKD.

Authors:  Nisha Bansal; Leila R Zelnick; Kristi Reynolds; Teresa N Harrison; Ming-Sum Lee; Daniel E Singer; Sue Hee Sung; Dongjie Fan; Alan S Go
Journal:  J Am Soc Nephrol       Date:  2021-12-17       Impact factor: 10.121

Review 3.  Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review.

Authors:  Stefano Ballestri; Elisa Romagnoli; Dimitriy Arioli; Valeria Coluccio; Alessandra Marrazzo; Afroditi Athanasiou; Maria Di Girolamo; Cinzia Cappi; Marco Marietta; Mariano Capitelli
Journal:  Adv Ther       Date:  2022-10-16       Impact factor: 4.070

4.  Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.

Authors:  Wayne A Ray; Cecilia P Chung; C Michael Stein; Walter Smalley; Eli Zimmerman; William D Dupont; Adriana M Hung; James R Daugherty; Alyson Dickson; Katherine T Murray
Journal:  JAMA       Date:  2021-12-21       Impact factor: 157.335

5.  Impact of atrial fibrillation on the risk of ischemic stroke in patients on hemodialysis: BOREAS-HD3 Study.

Authors:  Ayumu Kimura; Marenao Tanaka; Norihito Moniwa; Arata Osanami; Koki Abe; Daisuke Miyamori; Yufu Gocho; Satoru Shibata; Makoto Terasawa; Yusuke Okazaki; Tomohisa Yamashita; Masayuki Koyama; Masato Furuhashi; Hirofumi Ohnishi; Tetsuji Miura
Journal:  Clin Exp Nephrol       Date:  2020-11-18       Impact factor: 2.801

6.  Anticoagulant strategies for the patient with chronic kidney disease.

Authors:  Jonathan P Law; Luke Pickup; Jonathan N Townend; Charles J Ferro
Journal:  Clin Med (Lond)       Date:  2020-03       Impact factor: 2.659

7.  Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis.

Authors:  Chen Chen; Yalin Cao; Ying Zheng; Yugang Dong; Jianyong Ma; Wengen Zhu; Chen Liu
Journal:  Cardiovasc Drugs Ther       Date:  2021-02-04       Impact factor: 3.727

Review 8.  Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation.

Authors:  Gianluca Botto; Pietro Ameri; Manuel Cappellari; Francesco Dentali; Nicola Ferri; Iris Parrini; Italo Porto; Alessandro Squizzato; Giuseppe Camporese
Journal:  Adv Ther       Date:  2021-05-21       Impact factor: 3.845

9.  Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.

Authors:  Hang-Long Li; Gregory-Y H Lip; Qi Feng; Yue Fei; Yi-Kei Tse; Mei-Zhen Wu; Qing-Wen Ren; Hung-Fat Tse; Bernard-M Y Cheung; Kai-Hang Yiu
Journal:  Cardiovasc Diabetol       Date:  2021-05-07       Impact factor: 9.951

Review 10.  Risk Factors for CKD Progression: Overview of Findings from the CRIC Study.

Authors:  Mary Hannan; Sajid Ansari; Natalie Meza; Amanda H Anderson; Anand Srivastava; Sushrut Waikar; Jeanne Charleston; Matthew R Weir; Jonathan Taliercio; Edward Horwitz; Milda R Saunders; Katherine Wolfrum; Harold I Feldman; James P Lash; Ana C Ricardo
Journal:  Clin J Am Soc Nephrol       Date:  2020-11-11       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.